SOURCE-LINKED STUDY SUMMARY
Efficacy and Safety of Lonapegsomatropin in Children With Turner Syndrome: 52-Week Results From the New InsiGHTS Trial.
Abstract summarizedQuality not appraised
- What was studied
- A randomized phase 2 trial compared weekly lonapegsomatropin with daily somatropin for growth in Turner syndrome.
- Who / model studied
- 49 prepubertal children were enrolled and dosed, according to the publication.
- Studied dose & schedule
- Weekly subcutaneous lonapegsomatropin starting doses: 0.24, 0.30 or 0.36 mg hGH/kg/week. Daily somatropin totaled 0.35 mg/kg/week, not per day; 52 weeks.
- What the study found
- Primary week-26 annualized height velocity was 9.23–10.36 cm/year across weekly starting-dose groups versus 10.86 with daily treatment. Secondary week-52 rates were 9.05 pooled versus 9.04 cm/year. The abstract reported similar tolerability.
- Limitations & context
- Small open-label study; similarity does not establish formal equivalence. Abstract assessment lacked detailed adverse-event counts and confidence intervals. Registry enrollment differs from the paper. Pediatric height results cannot establish adult muscle benefits.
Read summary source ↗ · Prepared 10/28/2026 · AI-assisted, source-based summary
Review record & corrections
Summary prepared: . Source scope: abstract. This is an AI-assisted source summary, not an independent clinician sign-off.
No public field-by-field revision history is available for this card yet. The date above is the summary date, not proof that every field was updated then.
Inspect the source · Correction policyResearch findings apply to the population and conditions studied. This educational summary is not a treatment recommendation or a formal assessment of study quality.
Original publication ↗ · DOI: 10.1210/clinem/dgag436